What kind of medicine is Ivonib/Tosuvo and what are its special functions?

Ivosidenib/Tosovo (Ivosidenib) is an innovative targeted anti-cancer drug, which is a small molecule IDH1 inhibitor. It mainly targets tumors caused by IDH1 gene mutations, and has significant application value in acute myeloid leukemia (AML) and certain types of solid tumors. IDH1 gene mutations can cause abnormal metabolism of cancer cells and produce 2-hydroxyglutarate (2-HG), thereby inhibiting cell differentiation and promoting tumor growth. Ivonib selectively inhibits the activity of mutant IDH1 enzyme, prevents the production of 2-HG and restores cell differentiation ability, thereby delaying or inhibiting tumor progression.

Tosovo's special function lies not only in directly inhibiting the mutated enzyme, but also in its targeted precision therapeutic properties. Compared with traditional chemotherapy drugs, ivonib's targeting mechanism causes less damage to normal cells, more controllable side effects, and better tolerance by patients. This feature is particularly important in the long-term management of AML patients, as chemotherapy drugs are often associated with myelosuppression and infection risks, and avosidenib provides a new treatment option for patients with limited tolerance. In addition, the drug's potential in combination therapy has also attracted much attention, such as combined with low-dose chemotherapy drugs or other targeted drugs, which may improve the treatment effect of drug-resistant patients.

In clinical practice, ivonib is commonly usedin personalized treatment plans for patients with IDH1 mutation-positive acute myeloid leukemia, including relapsed or refractory AML, as well as some treatment-naïve patients. Oral administration of drugs improves patient compliance and makes treatment more convenient while reducing the discomfort and risks associated with intravenous infusion. Since ivonib has a clear targeting mechanism, genetic testing is usually required to confirm the IDH1 mutation status before use.

Reference: https://www.tibsovo.com/